Royalty Pharma plc

Royalty Pharma plc is a leading financier in the biopharmaceutical sector, specializing in the acquisition of royalty interests in approved and late-stage drug products. Founded in 1996 by Pablo Legorreta, the company's core mission is to fund innovation across the biopharmaceutical industry by providing non-dilutive capital to drug developers. Headquartered in New York City, United States, Royalty Pharma operates at the intersection of science, medicine, and investing, aiming to bridge the gap between innovative ideas and market-ready solutions.

The company's business model revolves around acquiring rights to future royalty payments from biopharmaceutical products, as well as co-funding late-stage clinical trials and new product launches in exchange for future royalties. This strategy allows drug developers to access essential capital without equity dilution, supporting critical research and development. Royalty Pharma has built a diversified portfolio, holding royalties on over 35 commercial products and numerous development-stage candidates across key therapeutic areas such as oncology, neurology, infectious diseases, and rare diseases. Notable products in its portfolio include Imbruvica, Tysabri, Vertex's cystic fibrosis franchise, and Xtandi.

As the world's largest buyer of biopharmaceutical royalties, Royalty Pharma holds a significant global market share in biopharma royalty transactions. Recent strategic developments include the appointment of Lucas Glass as Head of Artificial Intelligence, Greg Butz as Executive Vice President, Partnering & Investments, and Kenneth Sun as Senior Vice President and Head of Asia, reflecting an expansion of its leadership team. In April 2026, the company declared a second-quarter dividend of $0.235 per Class A ordinary share and launched the Royalty Pharma Translational Prize to recognize breakthrough scientific innovation. Additionally, Royalty Pharma announced a $500 million R&D co-funding agreement with Johnson & Johnson for 2026 and 2027 to advance an investigational medicine for autoimmune diseases.